Northern Trust Corp Annovis Bio, Inc. Transaction History

Northern Trust Corp

$761 Billion
Q3 2025

A detailed history of Northern Trust Corp transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 121,060 shares of ANVS stock, worth $279,648. This represents 0.0% of its overall portfolio holdings.

Number of Shares

121,060

Previous 59,514 103.41%

Holding current value

$279,648

Previous $129,000 93.02%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$1.97 - $2.93 $121,245 - $180,329	61,546 Added 103.41%	121,060 $249,000
Q2 2025 Aug 13, 2025	BUY	$1.22 - $3.24 $22,978 - $61,025	18,835 Added 46.3%	59,514 $129,000
Q1 2025 May 13, 2025	BUY	$1.5 - $5.39 $11,848 - $42,575	7,899 Added 24.1%	40,679 $61,000
Q4 2024 Feb 14, 2025	BUY	$4.37 - $9.87 $47,397 - $107,050	10,846 Added 49.45%	32,780 $164,000
Q3 2024 Nov 13, 2024	BUY	$5.27 - $15.46 $14,223 - $41,726	2,699 Added 14.03%	21,934 $176,000

Q2 2024 Aug 14, 2024	SELL	$4.82 - $18.01 $24,254 - $90,626	-5,032 Reduced 20.74%	19,235 $110,000
Q1 2024 May 14, 2024	SELL	$8.47 - $18.93 $40,495 - $90,504	-4,781 Reduced 16.46%	24,267 $288,000
Q4 2023 Feb 13, 2024	BUY	$5.55 - $19.62 $104,717 - $370,190	18,868 Added 185.34%	29,048 $543,000
Q2 2023 Aug 11, 2023	BUY	$11.95 - $16.31 $121,651 - $166,035	10,180 New	10,180 $145,000
Q4 2021 Feb 08, 2022	SELL	$17.58 - $37.67 $159,942 - $342,721	-9,098 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$21.55 - $96.1 $36,053 - $160,775	1,673 Added 22.53%	9,098 $779,000
Q1 2021 May 12, 2021	BUY	$8.15 - $38.44 $60,513 - $285,417	7,425 New	7,425 $207,000

Others Institutions Holding ANVS

# of Institutions

Shares Held

2.03M

Call Options Held

167K

Put Options Held

97.2K

View Full List

About Annovis Bio, Inc.

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $18.9M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

More about ANVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Annovis Bio, Inc. Transaction History